Sex and age differences in sST2 in cardiovascular disease
Authors:
Open Access
- 18 January 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 1073814
Abstract
Aims: The goal of this study was to determine whether sex and age differences exist for soluble ST2 (sST2) for several cardiovascular diseases (CVDs).Methods: We examined sST2 levels using an ELISA kit for myocarditis (n = 303), cardiomyopathy (n = 293), coronary artery disease (CAD) (n = 239), myocardial infarct (MI) (n = 159), and congestive heart failure (CHF) (n = 286) and compared them to controls that did not have CVDs (n = 234).Results: Myocarditis occurred in this study in relatively young patients around age 40 while the other CVDs occurred more often in older individuals around age 60. We observed a sex difference in sST2 by age only in myocarditis patients (men aged 38, women 46, p = 0.0002), but not for other CVDs. Sera sST2 levels were significantly elevated compared to age-matched controls for all CVDs: myocarditis (p ≤ 0.0001), cardiomyopathy (p = 0.0009), CAD (p = 0.03), MI (p = 0.034), and CHF (p < 0.0001) driven by elevated sST2 levels in females for all CVDs except myocarditis, which was elevated in both females (p = 0.002) and males (p ≤ 0.0001). Sex differences in sST2 levels were found for myocarditis and cardiomyopathy but no other CVDs and were higher in males (myocarditis p = 0.0035; cardiomyopathy p = 0.0047). sST2 levels were higher in women with myocarditis over 50 years of age compared to men (p = 0.0004) or women under 50 years of age (p = 0.015). In cardiomyopathy and MI patients, men over 50 had significantly higher levels of sST2 than women (p = 0.012 and p = 0.043, respectively) but sex and age differences were not detected in other CVDs. However, women with cardiomyopathy that experienced early menopause had higher sST2 levels than those who underwent menopause at a natural age range (p = 0.02).Conclusion: We found that sex and age differences in sera sST2 exist for myocarditis, cardiomyopathy, and MI, but were not observed in other CVDs including CAD and CHF. These initial findings in patients with self-reported CVDs indicate that more research is needed into sex and age differences in sST2 levels in individual CVDs.Keywords
Funding Information
- National Institutes of Health (R01 HL164520, R21 AI145356, R21 AI152318, R21 AI154927, UL1 TR002377, TL1 TR002380, R21 AI163302, R01 HL135165, R01 HL56267)
- American Heart Association (20TPA35490415)
- Ministerstvo Zdravotnictví Ceské Republiky (NU22-02-00418)
This publication has 62 references indexed in Scilit:
- Distribution and Clinical Correlates of the Interleukin Receptor Family Member Soluble ST2 in the Framingham Heart StudyClinical Chemistry, 2012
- IL-33 Independently Induces Eosinophilic Pericarditis and Cardiac DilationCirculation: Heart Failure, 2012
- Testosterone and interleukin-1β increase cardiac remodeling during coxsackievirus B3 myocarditis via serpin A 3nAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- Th2 Regulation of Viral Myocarditis in Mice: Different Roles for TLR3 versus TRIF in Progression to Chronic DiseaseJournal of Immunology Research, 2011
- Efficacy and Safety of Exercise Training in Patients With Chronic Heart FailureJAMA, 2009
- Nonmyocardial Production of ST2 Protein in Human Hypertrophy and Failure Is Related to Diastolic LoadJACC, 2008
- Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart FailureJACC, 2008
- Sex Differences in Autoimmune Disease from a Pathological PerspectiveThe American Journal of Pathology, 2008
- Predictors of Outcome in Patients With Suspected MyocarditisCirculation, 2008
- Tissue Distribution and Subcellular Localization of a Variant Form of the Human ST2 Gene Product, ST2VBiochemical and Biophysical Research Communications, 2001